Jens Chemnitz

CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition

Michael S. von Bergwelt‐Baildon, Alexey Popov, Tomo Šarić et al. · Blood · 2006 · 242 citations · Full text

Life Sciences, Immunology, Oncology +15

Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas

Nora Liebers, Johannes Duell, Donnacha Fitzgerald et al. · Blood Advances · 2021 · 92 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Brentuximab Vedotin Combined With Donor Lymphocyte Infusions for Early Relapse of Hodgkin Lymphoma After Allogeneic Stem-Cell Transplantation Induces Tumor-Specific Immunity and Sustained Clinical Remission

Sebastian Theurich, Joke Malcher, Kerstin Wennhold et al. · Journal of Clinical Oncology · 2012 · 67 citations

Medicine, Hematology, Immunology +17

Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia

Christina Rautenberg, Friedrich Stölzel, Christoph Röllig et al. · Blood Cancer Journal · 2021 · 65 citations · Full text

Medicine, Hematology, Cancer Drug Toxicity Management +15

Successful peripheral blood stem cell mobilization with etoposide (VP-16) in patients with relapsed or resistant lymphoma who failed cyclophosphamide mobilization

Marcel Reiser, Andreas Josting, Andreas Draube et al. · Bone Marrow Transplantation · 1999 · 48 citations

Medicine, Hematology, Oncology +14